ESMO Virtual Journal Club
A new ESMO webinar series where oncology experts discuss and critically evaluate notable recent publications with an aim to enhance understanding and application of the latest research in the field.
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
A new ESMO webinar series where oncology experts discuss and critically evaluate notable recent publications with an aim to enhance understanding and application of the latest research in the field.
The EHDS can contribute to boosting cancer research by facilitating the (re)use of existing data sources - in anonymised or pseudorandomised format - for research and innovation in oncology
The tyrosine kinase inhibitor showed to prolong disease-free survival as compared to chemotherapy and clinically meaningful benefit with respect to CNS disease–free survival
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.